

**NAVANA PHARMA****NAVANA PHARMACEUTICALS PLC.**Corporate Office : House # 99, Road #04, Block # B,
Banani, Dhaka -1213**PRICE SENSITIVE INFORMATION**

This is for kind information to all valued shareholders of Navana Pharmaceuticals PLC. and stakeholders that the Board of Directors of the company in its 47th meeting held on Monday, 28th October, 2024 ended at 4.00 p.m. at its Corporate office at House 99, Road 4, Block #B, Banani Dhaka -1213, has considered and approved, among others, the Audited Financial Statement for the year ended on June 30, 2024 and took the following Price Sensitive Decisions:-

a. Information Relating 38th Annual General Meeting (AGM):

- ★ Recommended Dividend : **14 % Cash only for general shareholders** (Sponsor shareholders & Directors and few shareholders who hold significant share of the company will not receive any dividend)
Total Paid-up share 107,416,217, Director & Sponsor are hold 38,857,014 nos. shares & 34,665,622 nos. share are hold other shareholder who are willingly forgo their dividend along with Director & Sponsor for the betterment of the company. Whereas BDT 47,451,014 payable to the General Shareholders as 14% cash dividend.
- ★ Record Date : Tuesday, November 19, 2024
- ★ Date of the 38th AGM : December 31, 2024
- ★ Mode of the 38th AGM : Hybrid
- ★ Venue of hybrid AGM : Registered office: 1071, 1073, North Rupshi, Tarabo Municipality, Rupganj, Narayanganj
- ★ Time of hybrid AGM : 3.30 PM
- ★ Virtual Link of hybrid AGM : Will be notified later on due course.

b. The key comparative financial disclosure on Audited Financial Statement for the year ended on June 30, 2024 as follows:

Sl. No.	Particulars	2023 - 2024	2022 - 2023
I.	Earnings per Share (EPS)	3.77	3.59
II.	Net Asset Value (BDT in Million)	4,561.10	4,372.45
III.	Net Asset Value per Share (NAV) (BDT)	42.46	40.71
IV.	Net Operating Cash Flow per Share (NOCFPS) (BDT)	6.58	1.80

c. Explanatory notes for the significant variation in the Financial Statements for the year ended June 30, 2024:

Issue-1: Net Operating Cash Flow per Share (NOCFPS):

Net Operating Cash Flow per Share (NOCFPS) has increased to Tk. 6.58 from Tk. 1.80, due to cash received from customers was higher than the cash payment to the vendors.

Notes:

- ★ The shareholders whose name will appear in the Depository Register (CDBL) or register folio the member of the company on the "Record Date" i.e. 19 November, 2024 will be titled to attend in the Annual General Meeting and to receive the dividend.
- ★ Members are requested to update their Bank Account Number, Taxpayer's Identification Numbers (e-TIN), Address, E-mail address and cell no before the record date of their respective depository participant.
- ★ The concerned brokerage houses & merchant bankers are requested to provide us with a statement with the details (shareholders name, BOID number, e-TIN number, gross dividend receivable, applicable tax rate, and net dividend receivable) of their margin loan holders who hold shares of the Company as on the Record Date, along with the name of the contact person in this connection. The brokerage houses & merchant bankers are also requested to provide us with their Bank Account Name, Number, Routing number etc. on or before 10 December 2024.
- ★ In compliance with Listing Regulation 2015 of Dhaka Stock Exchange PLC. and Chittagong Stock Exchange PLC., the company will publish the details Annual Audited Financial Statement in its website (www.navanapharma.com).

Dated: October 28, 2024

By order of the Board
Sd/-**Lorens Shamol Mollick FCS**
Company Secretary